Gilead Files Next HIV Triple-Combo Pill, With Hopes Of Prophylaxis Claim; Can Firm Recreate HIV Success In Hep C?
This article was originally published in Pharmaceutical Approvals Monthly
Gilead Sciences, Inc. has filed an NDA for a triple-combination HIV pill that could supplant its existing Atripla, which will face generic pressure in 2013. The company announced Nov. 23 that it has filed for FDA approval of a single-tablet regimen containing its Truvada (emtricitabine/tenofovir) plus Johnson & Johnson's investigational non-nucleoside reverse transcriptase inhibitor rilpivirine, also known as TMC278.
You may also be interested in...
Solid efficacy with fewer psych effects than Atripla continue in full-length version of Phase II trials. However, hopes for superior performance have started to wane.
Johnson & Johnson subsidiary Tibotec has submitted its once-daily non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine) for treatment-naïve HIV patients for FDA approval, close on the heels of releasing pivotal data at the International AIDS Society meeting in Vienna
After US President Trump said vaccine developers could develop a COVID-19 vaccine faster if it weren't for politics, Moderna CEO Bancel said no political party has asked the company to move faster or slower.